Lifecore Biomedical’s (LFCR) Outperform Rating Reiterated at Barrington Research

Barrington Research restated their outperform rating on shares of Lifecore Biomedical (NASDAQ:LFCR) in a report issued on Tuesday,Benzinga reports. They currently have a $5.50 price target on the stock.

A number of other analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Zacks Research raised shares of Lifecore Biomedical to a “hold” rating in a report on Thursday, January 1st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Lifecore Biomedical Trading Down 7.6%

LFCR stock opened at $3.87 on Tuesday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a 1-year low of $3.86 and a 1-year high of $8.98. The business has a 50 day simple moving average of $6.95 and a two-hundred day simple moving average of $7.29. The company has a market capitalization of $145.05 million, a price-to-earnings ratio of -3.95 and a beta of 0.62.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. The company had revenue of $35.75 million for the quarter, compared to the consensus estimate of $35.31 million. Research analysts anticipate that Lifecore Biomedical will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Lifecore Biomedical

Institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after buying an additional 1,886 shares in the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Lifecore Biomedical by 8.4% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 32,761 shares of the company’s stock valued at $266,000 after buying an additional 2,528 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after acquiring an additional 2,786 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Lifecore Biomedical by 20.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock valued at $137,000 after acquiring an additional 2,826 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in Lifecore Biomedical by 28.4% in the fourth quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock worth $132,000 after acquiring an additional 3,574 shares in the last quarter. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.